GB1533464A - Cancer diagnostic agents - Google Patents
Cancer diagnostic agentsInfo
- Publication number
- GB1533464A GB1533464A GB6357/76A GB635776A GB1533464A GB 1533464 A GB1533464 A GB 1533464A GB 6357/76 A GB6357/76 A GB 6357/76A GB 635776 A GB635776 A GB 635776A GB 1533464 A GB1533464 A GB 1533464A
- Authority
- GB
- United Kingdom
- Prior art keywords
- recognin
- dissolved
- solubilised
- tissue
- recognins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4731—Recognins, e.g. malignin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
In the process for the preparation of recognins, optionally provided with a carrier, normal or diseased tissue is extracted with a neutral buffer with repeated disintegration of the tissue. By this means, protein fractions are dissolved or solubilised. Extraction is then carried out. The fraction having a pK range of 1 to 4 is separated off from the resulting extract of the dissolved or solubilised proteins. This is achieved by adding the extract of the dissolved or solubilised proteins to a chromatographic column and eluting with increasingly acidic solvents. A product is isolated therefrom having a molecular weight of 3,000 to 25,000. The isolation is carried out by filtering the eluate in order to obtain a fraction which contains recognin. The recognin is separated therefrom by thin-layer gel chromatography. The recognin obtained is optionally mixed with a carrier for the purpose of forming a complex compound. This process enables the preparation of recognins which are used for diagnosis and for control of malignant tissue.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55043275A | 1975-02-18 | 1975-02-18 | |
US55307575A | 1975-02-25 | 1975-02-25 | |
US62111275A | 1975-10-09 | 1975-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1533464A true GB1533464A (en) | 1978-11-22 |
Family
ID=27415588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB6357/76A Expired GB1533464A (en) | 1975-02-18 | 1975-10-15 | Cancer diagnostic agents |
Country Status (4)
Country | Link |
---|---|
JP (2) | JPH0146520B2 (en) |
CH (1) | CH639102A5 (en) |
DE (1) | DE2606257A1 (en) |
GB (1) | GB1533464A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0015755A2 (en) * | 1979-03-09 | 1980-09-17 | Samuel Dr. Bogoch | Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0007214B1 (en) * | 1978-07-07 | 1985-10-23 | Samuel Dr. Bogoch | Product for detecting the presence of cancerous or malignant tumor cells |
CH645728A5 (en) * | 1979-01-30 | 1984-10-15 | Otsuka Pharma Co Ltd | PROCESS FOR DETERMINING THE CONTENT OF SUBSTANCES CONTAINING GLUCOSIDIC BONDS ASSOCIATED WITH TUMORS, APPLICATION OF THIS PROCESS AND NECESSARY FOR ITS IMPLEMENTATION. |
-
1975
- 1975-10-15 GB GB6357/76A patent/GB1533464A/en not_active Expired
- 1975-10-16 CH CH1343075A patent/CH639102A5/en not_active IP Right Cessation
-
1976
- 1976-02-17 DE DE19762606257 patent/DE2606257A1/en not_active Withdrawn
- 1976-02-18 JP JP51017432A patent/JPH0146520B2/ja not_active Expired
-
1988
- 1988-05-30 JP JP63130488A patent/JPH01112163A/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0015755A2 (en) * | 1979-03-09 | 1980-09-17 | Samuel Dr. Bogoch | Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors |
EP0015755A3 (en) * | 1979-03-09 | 1980-12-10 | Samuel Dr. Bogoch | Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors |
Also Published As
Publication number | Publication date |
---|---|
DE2606257A1 (en) | 1976-08-26 |
JPH0257671B2 (en) | 1990-12-05 |
JPS51108001A (en) | 1976-09-25 |
CH639102A5 (en) | 1983-10-31 |
JPH0146520B2 (en) | 1989-10-09 |
JPH01112163A (en) | 1989-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU41776A (en) | Process for obtaining protein concentrates suitable as foodstuffs by separation of phenol and oligosaccharides from vegetable tissues | |
NL7612673A (en) | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS AS AVAILABLE FOR THE TREATMENT OF CALCIUM SUBSTANCE INTERFERENCES. | |
Swager et al. | Coumarins from Musineon divaricatum | |
Kessel et al. | Purification and analysis of hematoporphyrin and hematoporphyrin derivative by gel exclusion and reverse‐phase chromatography | |
GB1533464A (en) | Cancer diagnostic agents | |
EP0216936A4 (en) | Novel tannin composition. | |
NL7606612A (en) | PROCESS FOR THE PREPARATION OF NEW PHARMACEUTICAL PREPARATIONS. | |
Herring et al. | The isolation of soluble proteins, glycoproteins, and proteoglycans from bone | |
NL188948B (en) | PROCESS FOR THE PREPARATION OF PYRIDO (1,2A) PYRIMIDINES, ANTI-INFLAMMATION AND BLOOD CLOTTING PROCESS, AND PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONTAINING THESE. | |
NL7711916A (en) | PROCESS FOR PREPARING HIGHLY CONCENTRATED PHARMACEUTICAL PREPARATIONS OF STEROIDS. | |
Okudaira et al. | Cytotoxic factor demonstrated in lymph node extract | |
Lunde | Location of lipid‐soluble selenium in marine fish to the lipoproteins | |
ES437046A2 (en) | Manufacture of novel amino acid derivative | |
Peralta et al. | (-)-epicatechin-3-galloyl ester: a secretagogue compound from the bark of Sclerocarya birrea | |
GB1430885A (en) | Process for preparing a purified extract of quillaia bark | |
Miccio et al. | Bilitranslocase is the protein responsible for the electrogenic movement of sulfobromophthalein in plasma membrane vesicles from rat liver: immunochemical evidence using mono-and poly-clonal antibodies | |
Dickinson et al. | The chemical nature of cancer basic protein | |
Axelsson et al. | Identification of bufotenin in toad brain by chromatography and mass spectrometry of its dans-derivative | |
ES447851A1 (en) | Process for the extraction of components having anticoagulant activity {37 in vivo{38 {0 from snake venoms and products obtained | |
OHASHI et al. | Purification of toxohormone by DEAE-cellulose columnchromatography | |
ES388011A1 (en) | Process for the production of pigmented coating powders | |
NL7607693A (en) | PROCESS FOR THE PREPARATION OF ANTI-BLOOD-PRESSURE-ACTING PREPARATIONS. | |
Helmy et al. | An ethanolamine plasmalogen artifact formed by acetone extraction of freeze-dried tissue | |
DE2967143D1 (en) | Diagnostic method, especially for the early recognition of malignant tumors and/or viral diseases, and means to carry it out | |
GB1443053A (en) | Cancer associated polypeptide antigen process for its pre paration and composition useful as an immunizing agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee | ||
728C | Application made for restoration (sect. 28/1977) | ||
728A | Order made restoring the patent (sect. 28/1977) | ||
PCNP | Patent ceased through non-payment of renewal fee |